All
Avirmax Biopharma prepares for IND-enabling study of ABI-201
ABI-201 aims to prevent dry AMD and other retinal disorders in patients.
EMA provides positive ATMP opinion for gene therapy products OCU410 and OCU410ST
The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease.
Data from Phase 2b of Opthea Limited wet AMD trial published
The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type.”
Adverum Biotechnologies initiates phase 3 ARTEMIS trial evaluating ixoberogene soroparvovec (Ixo-vec) in patients with wet AMD
Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette and is designed to be administered as a one-time intravitreal injection.
Pykus Therapeutics secures a new patent retinal sealant, PYK-2101
PYK-2101 is a first-in-class biodegradable retinal hydrogel sealant.
Companies to present at TC Cowen 45th Annual Health Care Conference
Apellis Pharmaceuticals and EyePoint Pharmaceuticals are both scheduled to present at the conference.
The retinal thickness and choroidal vascularity index in smokers
Outlook Therapeutics resubmits BLA for ONS-5010 for treatment of wet AMD
If approved, the drug will be branded as LYTENAVA.
CDR-Life completes fifth milestone and is recruiting patients for Phase 2 study of BI 771716
This follows successful Phase 1 results, which demonstrated a favorable safety profile for BI 771716 across both single and multiple intravitreal doses.
Cognition Therapeutics announces manuscript publication on oral drug candidate zervimesine (CT1812) for treatment of dry AMD
The company also reported a positive outcome of an analysis of masked data from its ongoing MAGNIFY Phase 2 trial for zervimesine in adults with GA.
Diagnos Inc to submit FDA pre-market authorization for CARA SYSTEM
This device is designed to assist healthcare professionals in analyzing fundus images for the early detection of key retinal conditions.
Study demonstrates visual acuity improvements following gene therapy for AIPL1-associated inherited retinal dystrophies
Researchers indicated that pediatric patients with Leber congenital amaurosis experienced improvements in vision.
Alkeus Pharmaceuticals establishes new Scientific Advisory Board
The intent is that the board provide strategic guidance and expert insights to support the development of the company’s programs and science.
UK MHRA issues approval for aflibercept biosimilar FYB203 (AHZANTIVE) from Formycon
The biosimilar to aflibercept (Eylea) had already received approval in the EU and US.
FDA grants RMAT designation to RPESC-RPE-4W transplantation for AMD
RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells.
Retinal detachment risk after B1KPro
Risk factors vary in both short-term and long-term periods following Boston Type 1 keratoprosthesis surgery.
Arctic Vision files New Drug Application in China for candidate to treat uveitic macular edema
Arctic Vision has a commercial collaboration agreement with Santen Pharmaceutical Co., Ltd. to commercialize ARVN001 for the treatment of UME.
Researchers collaborate on eye surgery robot at University of Utah
The researchers successfully tested the robot using enucleated pig eyes.
RetinalGenix Technologies starts imaging patients with prototype high-resolution retinal imaging device
The imaging system is designed to enable secure, real-time remote monitoring around the clock, from virtually any location.
National Eye Institute awards grant to support AI research for the diagnosis and treatment of uveitis
This research project, titled, “A Generalizable Deep Learning Platform for Unifying Quantification of Experimental Autoimmune Uveitis.”
Retinopathy of Prematurity (ROP) Awareness Week begins February 24, 2025
Prevent Blindness will be sharing a variety of free educational resources to the public and professionals during the awareness week, which will be held February 24, 2025, through March 2, 2025.
Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks
The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March
Sexual harassment remains high in ophthalmology
Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06
AVT06 is Alvotech’s proposed biosimilar to Eylea (aflibercept) 2mg.
Hyperacute outer retinal dysfunction: An underrecognized pediatric disorder?
Opthea Limited completes week 52 patient visits in the COAST trial
The topline results from the COAST trial is anticipated in early Q2 of 2025.
PulseSight Therapeutics SAS receives funds to support clinical trials of PST-611
PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.
Managing retinal detachment in morning glory syndrome
Optos ushers in new generation of imaging with MonacoPro ultra-widefield and OCT
MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.
Ocugen, Inc. completes dosing in Phase 2 portion of ArMaDa clinical trial for OCU410
OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.
